Browse our 650+ Publications​

Latest Publications

Distinct phenotypic states and spatial distribution of CD8 + T cell clonotypes in human brain metastases

Sudmeier LJ, et al.
Cell Reports Medicine
May 2022
Authors and Affiliates
Lisa J Sudmeier 1, Kimberly B Hoang 2, Edjah K Nduom 2, Andreas Wieland 3, Stewart G Neill 4, Matthew J Schniederjan 4, Suresh S Ramalingam 5, Jeffrey J Olson 2, Rafi Ahmed 6, William H Hudson 7; 1 Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. 2 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA, USA. 3 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. 4 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA. 5 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. 6 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: rahmed@emory.edu. 7 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: william.hudson@emory.edu.

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

Whangbo J, et al.
Blood Advances
May 2022
Authors and Affiliates
Jennifer Whangbo 1, Sarah Nikiforow 2, Haesook T Kim 2, Jonathan Wahl 2, Carol G Reynolds 3, Sharmila Chamling Rai 4, Soomin Kim 5, Andrew Thomas Burden 2, Ana Alho 6, João F Lacerda 7, Edwin P Alyea 8, Corey S Cutler 9, Vincent T Ho 2, Joseph H Antin 2, Robert J Soiffer 2, Jerome Ritz 2, John Koreth 2; 1 Boston Children's Hospital, United States. 2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. 3 Dana-Farber Cancer Institute, BOSTON, Massachusetts, United States. 4 Dana Farber Cancer Institute, Quincy, Massachusetts, United States. 5 Dana-Farber Cancer Institute, Seoul, Korea, Republic of. 6 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Algés, Portugal. 7 Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, Lisbon, Portugal. 8 Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, United States. 9 Dana Farber Cancer Institute, Boston, Massachusetts, United States.

Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy

Shanavas M, et al.
Clinical Translational Immunology
May 2022
Authors and Affiliates
Mohamed Shanavas 1,2, Soi-Cheng Law 1, Mark Hertzberg 3, Rodney J Hicks 4, John F Seymour 5, Zhixiu Li 6, Lilia Merida de Long 1, Karthik Nath 1, Muhammed B Sabdia 1, Jay Gunawardana 1, Maher K Gandhi 1,7, Colm Keane 1,7; 1 Mater Research University of Queensland Brisbane QLD Australia. 2 Department of Haematology Mater Hospital Brisbane QLD Australia. 3 Department of Haematology Prince of Wales Hospital and University of NSW Randwick NSW Australia. 4 Department of Cancer Imaging Peter MacCallum Cancer Centre East Melbourne Melbourne VIC Australia. 5 Department of Haematology Peter MacCallum Cancer Centre Royal Melbourne Hospital & University of Melbourne Parkville VIC Australia. 6 Centre for Genomics and Personalised Health School of Biomedical Sciences, Faculty of Health Translational Research Institute Queensland University of Technology (QUT) Woolloongabba QLD Australia. 7 Department of Haematology Princess Alexandra Hospital Brisbane QLD Australia.

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

Chen R, et al.
May 2022
Authors and Affiliates
Runzhe Chen 1,2,3, Jun Li 2,4, Junya Fujimoto 5, Lingzhi Hong 1, Xin Hu 2, Kelly Quek 1,2, Ming Tang 2, Akash Mitra 2, Carmen Behrens 1, Chi-Wan Chow 5, Peixin Jiang 1, Latasha D Little 2, Curtis Gumbs 2, Xingzhi Song 2, Jianhua Zhang 2, Dongfeng Tan 6, John V Heymach 1, Ignacio Wistuba 5, P Andrew Futreal 2, Don L Gibbons 7, Lauren A Byers 8, Jianjun Zhang 9,10, Alexandre Reuben 11; 1 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 2 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 3 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, Guangdong, China. 4 Regor Therapeutics, 2445 Main Street, Second Floor, MA, 02142, Cambridge, USA. 5 Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 6 Department of Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 7 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dlgibbon@mdanderson.org. 8 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. lbyers@mdanderson.org. 9 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org. 10 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org. 11 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. areuben@mdanderson.org.

SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection

Dykema AG, et al.
EBio Medicine
May 2022
Authors and Affiliates
Arbor G Dykema 1, Boyang Zhang 2, Bezawit A Woldemeskel 3, Caroline C Garliss 3, Rufiaat Rashid 1, Timothy Westlake 1, Li Zhang 1, Jiajia Zhang 1, Laurene S Cheung 1, Justina X Caushi 1, Drew M Pardoll 1, Andrea L Cox 4, Hongkai Ji 2, Kellie N Smith 5, Joel N Blankson 6; 1 Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. 2 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 3 Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 4 Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 5 Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Electronic address: ksmit228@jhmi.edu. 6 Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. Electronic address: jblanks@jhmi.edu.

ADXS31-142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

Stein MN, et al.
Oncologist
May 2022
Authors and Affiliates
Mark N Stein 1, Lawrence Fong 2, Ronald Tutrone 3, Anthony Mega 4, Elaine T Lam 5, Megan Parsi 6, Surya Vangala 6, Andres A Gutierrez 6, Naomi B Haas 7; 1 Columbia University Medical Center, New York, NY, USA. 2 University of California, San Francisco, CA, USA. 3 Chesapeake Urology Research Associates, Towson, MD, USA. 4 Lifespan Oncology Clinical Research, Rhode Island Hospital, Providence, RI, USA. 5 University of Colorado Cancer Center, University of Colorado Anschutz Medical Center, Aurora, CO, USA. 6 Advaxis, Monmouth Junction, NJ, USA. 7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.

Hultcrantz M, et al.
Clinical Cancer Research
May 2022
Authors and Affiliates
Malin Hultcrantz1,2, Even H. Rustad3, Venkata Yellapantula1, Allison Jacob4, Theresia Akhlaghi1,Neha Korde1, Sham Mailankody1, Alexander M. Lesokhin1, Hani Hassoun1, Eric L. Smith1, Oscar B. Lahoud5,Heather J. Landau5, Gunjan L. Shah5, Michael Scordo5, David J. Chung5, Sergio Giralt5, Elli Papaemmanuil3,and Ola Landgren6 1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Manhattan, New York. 2Karolinska Institute, Department of Medicine, Solna, Stockholm, Sweden. 3Department of Cancer Immunology, Oslo University Hospital Radiumhospitalet, Oslo, Norway. 4Adaptive Biotechnologies, Seattle, Washington. 5Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Manhattan, New York. 6Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Kater AP, et al.
NEJM Evidence
May 2022
Authors and Affiliates
Arnon P. Kater, M.D., Ph.D.,1 Carolyn Owen, M.D.,2 Carol Moreno, M.D.,3 George Follows, B.M.Bch., Ph.D.,4 Talha Munir, M.B.B.S.,5 Mark-David Levin, M.D.,6 Ohad Benjamini, M.D.,7 Ann Janssens, M.D., Ph.D.,8 Anders Osterborg, M.D., Ph.D.,9 Tadeusz Robak, M.D., Ph.D.,10 Martin Simkovic, M.D., Ph.D.,11 Don Stevens, M.D.,12 Sergey Voloshin, M.D., Ph.D.,13 Vladimir Vorobyev, Ph.D.,14 Loic Ysebaert, M.D., Ph.D.,15 Rui Qin, Ph.D.,16 Andrew J. Steele, Ph.D.,17 Natasha Schuier, M.D.,18 Kurt Baeten, Ph.D.,19 Donne Bennett Caces, M.D., Ph.D.,16 and Carsten U. Niemann, M.D., Ph.D.,20 for the GLOW Investigators 1 Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, on behalf of the HOVON CLL Working Group, Amsterdam 2 Tom Baker Cancer Centre, Calgary, Alberta, Canada 3 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona 4 Addenbrooke’s Hospital, Cambridge, UK 5 St James’s Hospital, Leeds, UK 6 Albert Schweitzer Hospital, Dordrecht, Netherlands 7 Sheba Medical Center, Ramat Gan, Israel 8 Universitaire Ziekenhuizen Leuven, Leuven, Belgium 9 Karolinska University Hospital, Stockholm 10 Medical University of Łodz, Copernicus Memorial Hospital, Łodz, Poland 11 University Hospital Hradec Kralove, Hradec Kralove, Czech Republic 12 Norton Cancer Institute, Louisville, KY 13 Russian Scientific Research Institute of Hematology and Transfusiology, St. Petersburg, Russia 14 S.P. Botkin Moscow City Clinical Hospital, Moscow 15 Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France 16 Janssen Research & Development, Raritan, NJ 17 Janssen Research & Development, San Diego, CA 18 Janssen Research & Development, Dusseldorf, Germany 19 Janssen Research & Development, Beerse, Belgium 20 Rigshospitalet Copenhagen University Hospital, Copenhagen

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer

Burton KA, et al.
JCO Precision Oncology
May 2022
Authors and Affiliates
Kimberly A Burton 1,2,3,4, Elisabeth Mahen 2,5,6, Eric Quentin Konnick 7, Sibel Blau 2,3, Michael O Dorschner 8,9,10, Arturo B Ramirez 11, Stephen C Schmechel 8, Chaozhong Song 2,5,6, Rahul Parulkar 12, Stephanie Parker 3,4, Francis Mark Senecal 3,4, Colin C Pritchard 7, Brigham H Mecham 13, Christopher Szeto 12, Patricia Spilman 14, Jingchun Zhu 15, Vijayakrishna K Gadi 16,17, Roy Ronen 18, Jackie Stilwell 11, Eric Kaldjian 11, Janusz Dutkowski 18, Stephen Charles Benz 12, Shahrooz Rabizadeh 14, Patrick Soon-Shiong 12,14, C Anthony Blau 2,5,6,19; 1 Department of Medicine, University of Washington, Seattle, WA. 2 Center for Cancer Innovation, University of Washington, Seattle, WA. 3 Northwest Medical Specialties, Puyallup and Tacoma, WA. 4 South Sound CARE Foundation, Seattle, WA. 5 Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA. 6 Department of Medicine/Hematology, University of Washington, Seattle, WA. 7 Department of Laboratory Medicine, University of Washington, Seattle, WA. 8 Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA. 9 Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA. 10 Center for Precision Diagnostics, University of Washington, Seattle, WA. 11 Rarecyte Inc, Seattle, WA. 12 NantHealth, Culver City, CA. 13 Trialomics, Seattle, WA. 14 ImmunityBio Inc, Culver City, CA. 15 Computational Genomics Lab, University of California at Santa Cruz, Santa Cruz, CA. 16 Department of Medicine, University of Illinois, Chicago, IL. 17 Fred Hutchinson Cancer Research Center, Seattle, WA. 18 Data4Cure Inc, La Jolla, CA. 19 All4Cure Inc, Seattle, WA.

KIR + CD8 + T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19

Li J, et al.
Science
May 2022
Authors and Affiliates
Jing Li 1, Maxim Zaslavsky 2, Yapeng Su 3, Jing Guo 4, Michael J Sikora 5, Vincent van Unen 1, Asbjørn Christophersen 6,7,8, Shin-Heng Chiou 1, Liang Chen 1, Jiefu Li 9, Xuhuai Ji 10, Julie Wilhelmy 1, Alana M McSween 1, Brad A Palanski 11, Venkata Vamsee Aditya Mallajosyula 1, Nathan A Bracey 1, Gopal Krishna R Dhondalay 12, Kartik Bhamidipati 13, Joy Pai 13, Lucas B Kipp 14, Jeffrey E Dunn 14, Stephen L Hauser 15, Jorge R Oksenberg 15, Ansuman T Satpathy 16, William H Robinson 17,18, Cornelia L Dekker 19, Lars M Steinmetz 5,20,21, Chaitan Khosla 11,22,23, Paul J Utz 1,18, Ludvig M Sollid 6,7,8,24, Yueh-Hsiu Chien 1,4, James R Heath 3,25, Nielsen Q Fernandez-Becker 26, Kari C Nadeau 1 12, Naresha Saligrama 1, Mark M Davis 1,9,4; 1 Institute of Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA. 2 Program in Computer Science, Stanford University, Stanford, CA, USA. 3 Institute for Systems Biology, Seattle, WA, USA. 4 Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 5 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. 6 K.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway. 7 Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 8 Department of Immunology, University of Oslo, Oslo, Norway. 9 The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA. 10 Human Immune Monitoring Center, Stanford University School of Medicine, Stanford, CA, USA. 11 Department of Chemistry, Stanford University, Stanford, CA, USA. 12 Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University, Stanford, CA, USA. 13 Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA. 14 Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. 15 Department of Neurology and UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. 16 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 17 VA Palo Alto Health Care System, Palo Alto, CA, USA. 18 Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA. 19 Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. 20 Stanford Genome Technology Center, Stanford University, Palo Alto, CA, USA. 21 European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany. 22 Department of Chemical Engineering, Stanford University, Stanford, CA, USA. 23 Stanford ChEM-H, Stanford University, Stanford, CA, USA. 24 Department of Immunology, Oslo University Hospital, Oslo, Norway. 25 Department of Bioengineering, University of Washington, Seattle, WA, USA. 26 Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, CA, USA.
Previous Next